Nanoparticulate Carriers for the treatment of Infectious Diseases and Cancer

Author(s): Neeraj Mishra

Journal Name: Current Molecular Pharmacology

Volume 14 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

[1]
Singh, L.; Kruger, H.G.; Maguire, G.E.M. Thavendran Govender and Raveen Parboosing, the role of nanotechnology in the treatment of viral infections. Ther. Adv. Infectious Dis., 2017, 4(4), 105-131.
[2]
Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer, 2005, 5(3), 161.
[3]
Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751.
[4]
Shi, J.; Votruba, A.R.; Farokhzad, O.C.; Langer, R. Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Lett., 2010, 10(9), 3223.
[5]
Swartz, M.A.; Hirosue, S.; Hubbell, J.A. Engineering approaches to Immunotherapy. Sci. Transl. Med., 2012, 4(148), 148-149.
[6]
Kearney, C.J.; Mooney, D.J. Macroscale delivery systems for molecular and cellular payloads. Nat. Mater., 2013, 12(11), 1004.
[7]
Albanese, A.; Tang, P.S.; Chan, W.C.W. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng., 2012, 14, 1.
[8]
Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev., 2015, 91, 3.
[9]
L.E. Gerlowski, L.E. and Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res., 1986, 31(3), 288.
[10]
Farokhzad, O.C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3(1), 16.
[11]
Burgess, P.; Hutt, P.B. Farokhzad, O.C.; Langer R.; Minick, S.; Zale, S. On firm ground: IP protection of therapeutic nanoparticles. Nat. Biotechnol., 2010, 28(12), 1267.
[12]
Sun, T.; Zhang, Y.S.; Pang, B.; Hyun, D.C.; Yang, M.; Xia, Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl., 2014, 53(46), 12320.
[13]
Sutradhar, K.B.; Amin, M.L. Nanotechnology in cancer drug delivery and selective targeting; ISRN Nanotechnol, 2014. 1-13.
[14]
Srinivasan, M.M.; Rajabi, M.; Mousa, S. Multifunctional nanomaterials and their applications in drug delivery and cancer therapy. Nanomaterials, 2015, 5(4), 1690.
[15]
Bregoli, L.; Movia, D.; Gavigan-Imedio, J.D.; Lysaght, J.; Reynolds, J.; Prina-Mello, A. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine, 2016, 12(1), 81-103.
[16]
Palazzolo, S.; Bayda, S.; Hadla, M.; Caligiuri, I.; Corona, G.; Toffoli, G.; Rizzolio, F. The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes. Curr. Med. Chem., 2018, 25, 4224-4268.
[17]
Yao, Y.; Zhou, Y.; Liu, L.; Xu, Y.; Chen, Q.; Wang, Y.; Wu, S.; Deng, Y.; Zhang, J.; Shao, A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance, Front. Mol. Biosci. 2020.
[http://dx.doi.org/10.3389/fmolb.2020.00193]
[18]
Bahrami, B.; Hojjat-Farsangi, M.; Mohammadi, H.; Anvari, E.; Ghalamfarsa, G.; Yousefi, M.; Jadidi-Niaragh, F. Nanoparticles and targeted drug delivery in cancer therapy. Immunol. Lett., 2017, 190, 64-83.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2021
Published on: 23 September, 2021
Page: [261 - 262]
Pages: 2
DOI: 10.2174/187446721403210706114224

Article Metrics

PDF: 144
HTML: 3